A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder (MDD)
Epistemonikos ID: 378247bcd1f341255a39d0fcd07098c5fd15087b
First added on: May 14, 2024